News

Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain
CAMBRIDGE, Massachusetts, May 14, 2024 – Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, today announced that it closed a Series B funding round of $33M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures,  PV Capital Management, and Catalyst Health Ventures.
Read more...‍

Brixton Biosciences' Neural Ice™ Therapy granted Breakthrough Device designation by the FDA
CAMBRIDGE, Massachusetts, Oct. 25, 2023 – Brixton Biosciences, a clinical-stage life sciences company developing novel therapies for chronic and acute pain, is delighted to announce that its groundbreaking Neural Ice™ Therapy has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
Read more...‍

Brixton logo
TechnologyAboutLeadershipNewsContact
©2024 Brixton Biosciences. All rights reserved. Version 1.7 | Privacy Policy | Terms of Use
This website describes our product, which has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device.